"We are very fortunate to have the opportunity to participate in these projects and explore the potential benefits of KL 4 surfactant to address unmet needs in acute lung injury," said Dr. Robert Segal, Sr. Vice President, Government and Academic Affairs at Discovery Labs. "While our short-term development priority is focused on neonatology applications, efforts such as these demonstrate the potential to apply and develop our technologies to advance new standards in respiratory critical care."
ALI is associated with conditions that either directly or indirectly injure the air sacs of the lung. ALI is a syndrome of inflammation and increased permeability of the lungs with an associated breakdown of the lungs' surfactant layer. Among the causes of ALI are complications typically associated with certain major surgeries, mechanical ventilator-induced lung injury (often referred to as VILI), severe acute respiratory syndrome (SARS), pneumonia and sepsis. Direct injury of the lung leading to ALI can also occur from radiation or caustic chemical exposure. There are a significant number of people at risk in the United States for ALI annually and there are no currently approved therapies other than supportive respiratory care. Despite recent advances in understanding the pathophysiology, treatment, and long-term outcome of acute lung injury, morbidity and mortality related to ALI remains high.
ABOUT DISCOVERY LABSDiscovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL 4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL 4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward-Looking Statements To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those related to Discovery Labs' research and development activities and efforts to secure federal funding under various grant programs are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any forward-looking statement in this release speaks only as of the date on which it is made. The Company assumes no obligation to update or revise any forward-looking statements.SOURCE Discovery Laboratories, Inc.